Vogenx Inc (VOGX) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
FRED Regime × Technicals: 27% of 52W Range • RSI-14 at 52.9 (NEUTRAL RANGE)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 56/100 (D+) score, VOGX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($24.68) or 200D SMA ($23.83) invalidates the momentum regime and cuts Target Base ($19.74) toward Bear Floor ($15.40).
Vogenx Inc (VOGX) surged +5.29% to $19.92, trading at 27% of its 52-week range ($12.95 – $38.41). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Gainers Biohaven (NYSE:BHVN) shares increased by 39.3% to $16.37 during Thursday's pre-market session. The company's market cap stands at $1.7 billion. Vogenx (NASDAQ:VOGX) stock rose 22.05% to $24.89. The
QuantumScape rises 9.1% after narrower loss and new solid-state battery production plans; SHFS leads gainers while POM and others fall premarket.
Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics (NASDAQ:TENX)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VOGX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VOGX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Vogenx Inc (VOGX) ranks #267 by composite RQD confidence (56/100, grade D+) and #519 by equity capitalization ($295.9M). Within this direct 5-issuer industry benchmark cohort, VOGX leads on earnings valuation at N/A trailing P/E, while IRD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently leads its immediate peer cohort in composite quantitative strength at 56/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VOGX
ACTIVE
Vogenx Inc | D+ | 56/100 | — | — | — | +5.29% | $295.9M | Benchmark Subject |
| IRD Opus Genetics Inc. | E | 32/100 | — | — | -35.0% | -0.81% | $303.7M | /ird-vs-vogx → |
| FULC Fulcrum Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | +0.53% | $288.0M | /fulc-vs-vogx → |
| BNTC Benitec Biopharma Inc. | D- | 37/100 | — | — | -35.0% | +0.34% | $308.1M | /bntc-vs-vogx → |
| GLSI Greenwich LifeSciences Inc. | D- | 41/100 | — | — | -35.0% | +3.77% | $278.9M | /glsi-vs-vogx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vogenx Inc (VOGX) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, VOGX closed FY2025 with $681.2K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $681.2K | — |
As of 2026-11-01, Vogenx Inc (NASDAQ: VOGX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $19.92 (+5.29% 1D, market cap $295.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, VOGX ranks #267 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VOGX carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IRD (Opus Genetics Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $303.7M) and FULC (Fulcrum Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $288.0M). Among the 5-stock peer group, VOGX leads on earnings multiple (N/A) while IRD leads on capital efficiency (-35.0% ROIC).
Per VOGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001903784), Vogenx Inc generated $0 in revenue, $0 in net income, and $0 in free cash flow against $681.2K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
VOGX last traded at $19.92 (+5.29% on volume of 75,381 shares), positioning the stock -19.29% below its 50-day simple moving average ($24.68) and -16.41% below its 200-day simple moving average ($23.83). Across its 52-week range of $12.95 to $38.41, VOGX sits at the 27.4% percentile with a 14-day RSI of 52.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($17.43 to $22.41).
Why VOGX Stock surged +5.29% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.